Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
11/2005
11/09/2005EP1480983B1 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
11/09/2005EP1456202B1 Benzothiazoles
11/09/2005CN1694900A EE3-protein family and corresponding DNA sequences
11/09/2005CN1694864A N-bridged selective androgen receptor modulators and methods of use thereof
11/09/2005CN1694702A Neurotrophic factor production promoter
11/08/2005US6963000 Benzothiazole derivatives with activity as adenosine receptor ligands
11/08/2005US6962996 Inhibitors of p38
11/08/2005US6962993 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/08/2005US6962936 Treating diseases such as cancer, inflammatory disorders, restenosis,
11/08/2005US6962933 cerebral hemorrhage/infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's/Parkinson's disease, amyotrophic lateral sclerosis, diabetes, osteoporosis, Creutzfeldt-Jakob disease or virus infections
11/08/2005US6962915 Antiinflammatory agents
11/03/2005WO2005103012A1 Hydrazino-substituted heterocyclic nitrile compounds and use thereof
11/03/2005US20050245597 Darifenacin solvate with toluene; mixing the free base with toluene to form the solvate, converting to the hydrate, addition salt formation with hydrogen bromide; high purity, extended shelf life; irritable bowel syndrome, incontinence and other gastrointestinal disorders
11/03/2005US20050245581 3-(2-Cyanophenyl)-5-(2-methoxyphenyl)-1-phenyl-1,2-dihydropyridin-2-one; antagonists of AMPA and kainate receptors; neuroprotectants; neurodegenerative diseases; Alzheinmer's disease; antiepileptic agents; antispasmodic agents; anxiolytic agents; ddrug abuse; nervous sytem disorders; antihypoxic agents
11/03/2005US20050245575 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
11/03/2005US20050245574 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
11/03/2005US20050245567 Novel quinuclidine derivatives and their use
11/03/2005US20050245537 Use of compounds having ccr antagonism
11/03/2005US20050244812 Kits and methods for detection of apoptotic cells
11/03/2005US20050244508 Anti-spasmodic comprising xenon
11/03/2005US20050244406 Monoclonal antibodies against extracellular loops of c5ar
11/03/2005CA2564568A1 Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
11/02/2005EP1591129A2 Use of neurotoxic component of botulinum toxin for treating pain associated with cervical dystonia or bepharospasm
11/02/2005EP1507758B1 Indole derivatives and their use as ligands for cb2 receptors
11/02/2005EP1501525B1 Method for producing preparations rich in tocotrienol
11/02/2005EP1237902B1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase
11/02/2005EP1083905B1 Medical use of a selective estrogen receptor modulator in combination with a sex steroide precursor
11/02/2005CN1691957A 蛋白酶抑制剂 Protease inhibitors
11/02/2005CN1225473C Method of preparing cyclic vasoactive peptides
11/01/2005US6960688 Use of compounds for the elevation of pyruvate dehydrogenase activity
11/01/2005US6960578 Glutamate receptor antagonists
11/01/2005US6960571 Methods and compositions for administration of iron for the treatment of restless leg syndrome
11/01/2005CA2383351C Xanthine derivatives as selective antagonists of a2b adenosine receptors
10/2005
10/27/2005WO2005100987A1 Novel ligand of g protein coupled receptor protein and use thereof
10/27/2005WO2005100563A1 Follistatin mutant polypeptide
10/27/2005WO2005100337A1 Substituted dioxolane derivatives and their use of preparing the neuroregulator
10/27/2005WO2005099760A1 Solid pharmaceutical preparation
10/27/2005WO2005099681A1 Tablet containing branched chain amino acid and process for producing the same
10/27/2005US20050239896 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke, depression, glaucoma
10/27/2005US20050239852 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239773 1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; analgesic; great selectivity to mu receptor; analgesic; pain relief, drug dependence, alcoholism; side effect reduction
10/27/2005US20050239698 placental growth factor (PLGF) capable of promoting neovascularization in the treatment of diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue, scleroderma and skin ageing due to exposure to chemicals or solar radiation
10/27/2005US20050239169 Nucleotide sequences coding seladin-1polypeptide for use in treatment and prevention of alzheimer's disease
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050238624 Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications
10/27/2005CA2562885A1 Follistatin variant polypeptide
10/27/2005CA2562391A1 Solid pharmaceutical preparation
10/26/2005EP1588727A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588726A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588718A1 Gene therapy of hepatocyte growth factor to enhance muscular and cutaneous flap survival
10/26/2005EP1588703A1 Fatigue reducing agent
10/26/2005EP1430056B1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
10/26/2005EP1289965B1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
10/26/2005EP0625048B2 Synthesis of human procollagens and collagens in recombinant dna systems
10/26/2005CN1688603A Treatment and prophylaxis with 4-1BB-binding agents
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688315A Use of selective COX-2 inhibitors for the treatment of urinary incontinence
10/26/2005CN1688198A Induction of gene expression using a high concentration sugar mixture
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224423C Pharmaceutical composition improved in peroral absorbability
10/25/2005US6958350 Chemical compounds
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
10/21/2005CA2504582A1 Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer
10/21/2005CA2504401A1 Drug delivery systems for the prevention of neointimal hyperlasia
10/20/2005WO2005097782A1 Piperidine derivative
10/20/2005US20050234248 Method of producing preparations rich in tocotrienol
10/20/2005US20050234118 Novel aryllimidazole derivatives, preparation and therapeutic used thereof
10/20/2005US20050234116 e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole; voltage-dependent anion channel, mitochondria porin modulator, apoptosis suppressor, mitochondria function ameliorator; Down syndrome, pigmentary degeneration of retina, alcoholic hepatitis or sideroblastic anemia
10/20/2005US20050234092 Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
10/20/2005US20050234081 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
10/20/2005US20050234079 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt
10/20/2005US20050234048 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease
10/20/2005US20050233452 Cell populations which co-express CD49c and CD90
10/20/2005US20050233328 Methods of identifying compounds that modulate protein activity
10/20/2005CA2560311A1 Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
10/19/2005EP1586329A1 Botulinum toxin pharmaceutical compositions
10/19/2005EP1585526A2 Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
10/19/2005EP1311263B1 Fused pyrrolocarbazoles against inflammation
10/19/2005EP1237539B1 Oral solution containing galanthamine and a sweetening agent
10/19/2005EP1200095B1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances
10/19/2005CN1684959A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors
10/19/2005CN1684673A Electrospun amorphous pharmaceutical compositions
10/19/2005CN1684594A Fruit and/or vegetable derived composition
10/19/2005CN1683365A Substituted dioxopentacyclic derivative and its use in preparing neuro regulator
10/19/2005CN1683340A 2-nitro-gen-dicyclic [2, 2, 1] hepta-5-ene-3-carboxylic derivative and its use preparing neuro regulator
10/19/2005CN1223340C Electrospun pharmaceutical compositions
10/18/2005US6956050 Imidazole compounds as anti-inflammatory and analgesic agents
10/18/2005US6956028 Administering pyrimidine nucleotide precursor where respiratory chain dysfunction is caused by mutation, deletion, or rearrangement of mitochondrial DNA, cytotoxic cancer chemotherapy agents, aging
10/18/2005US6955813 Therapy for injured muscles
10/18/2005US6955810 Method for the treatment of inflammatory disorders
10/18/2005CA2046265C Sulphured imadazole derivatives, their preparation process, the new intermediates obtained, their application as drugs and the pharmaceutical preparations containing them
10/13/2005WO2005095587A1 Process for producing somatic stem cell differentiated from embryonic stem cell and use of the same
10/13/2005WO2005095452A1 Calcium ion leakage inhibitors
10/13/2005WO2005094885A1 Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228055 Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof
10/13/2005US20050227997 Selective inhibition of aggrecanase in osteoarthritis treatment
1 ... 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 ... 233